Advances in Metastatic Non-small Cell Lung Cancer–Implications on Diagnosis and Treatment as We Head towards 2024
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".
Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 7810
Special Issue Editors
Interests: non-small cell lung cancer; predictive and prognostic biomarkers in lung cancers; immuno-oncology; precision medicine; health related quality of life; drug toxicity; patient-reported outcomes; health care disparities
Special Issue Information
Dear Colleagues,
Non-small-cell lung cancer (NSCLC) has the highest cancer-related mortality rate worldwide to this day. Oncogenes, tumor heterogeneity and variabilities in the tumor microenvironment may all contribute to cancer progression and metastases, with >50% being metastatic at diagnosis (mainly brain, bone, liver, and adrenal glands).
In the past decade, advances in identifying driver mutations have completely changed the therapeutic landscape of this disease. Targeted therapies such as osimertinib and other small-molecule tyrosine kinase inhibitors, are now widely used in clinical practice. At the same time, new therapeutic targets are also emerging, greatly extending the life expectancy of patients who carry these alterations. Immunotherapy has also significantly improved the prognosis and survival of NSCLC patients, even for traditionally frail patients who are not candidates for chemotherapy. We are increasingly able to apply the concept of “precision oncology” in our clinics today and focus on delivering therapies to our patients that are individualized to their specific needs.
This Special Issue aims to publish high-quality research and reviews on the pathogenesis and evolving treatment landscape (immunotherapy, targeted therapy, etc.) of metastatic NSCLC with a joint mission of combating this deadly cancer.
Dr. Nagashree Seetharamu
Dr. Morana Vojnic
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NSCLC
- oncogene
- metastases
- targeted therapy
- immunotherapy
- pathogenesis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.